Delaware
|
|
0-19437
|
|
11-2962080
|
(State or other jurisdiction of incorporation or organization)
|
|
(Commission
File Number)
|
|
(I.R.S. Employer
Identification Number) |
Title of each class
|
|
Trading symbol
|
|
Name of each exchange on which registered
|
Common Stock
$0.001 par value per share |
|
TRXC
|
|
NYSE American
|
|
|
|
|
|
|
|
|
|
|
|
TransEnterix, Inc.
|
||
|
|
|
||||
Date: March 19, 2020
|
|
|
|
/s/ Brett Farabaugh
|
||
|
|
|
|
Brett Farabaugh
|
||
|
|
|
|
Interim Chief Financial Officer
|
•
|
Three hospitals initiated Senhance Digital Laparoscopy Programs thus far in 2020
|
•
|
Announced FDA 510(k) clearance for First Machine Vision System in Robotic Surgery on March 13, 2020
|
•
|
Raised approximately $15 million in gross proceeds in an underwritten public offering in March of 2020 and $11.6 million in ATM offering gross proceeds since January 2020
|
•
|
Entered into an equity line purchase agreement on February 10, 2020 with Lincoln Park Capital Fund, LLC which provides access to up to $25 million
|
•
|
Received CE Mark approval for Pediatric indication for Senhance® Surgical System on February 12, 2020
|
•
|
Continued to execute restructuring plan to reduce cash burn
|
•
|
Expand the number of sites using the Senhance System in the United States, EMEA, and Japan and convert more existing sites into “foundational” sites that are on a rate to perform 100+ cases annually to drive meaningful clinical case volume growth;
|
•
|
Generate meaningful health economic data, primarily around the cost impact of Senhance relative to traditional laparoscopy as well as other surgical robotic systems; and,
|
•
|
Complete the following product portfolio initiatives:
|
○
|
launch the scene cognition and augmented intelligence module in the United States by mid-2020;
|
○
|
expand the European launch of 5mm Articulating Instruments and submit for U.S. clearance in the fourth quarter; and,
|
○
|
obtain a general surgery indication, including bariatrics in the U.S.
|
|
|
Three Months Ended
|
|
|
Twelve Months Ended
|
|
||||||||||||||
|
|
December 31,
|
|
|
December 31,
|
|
||||||||||||||
|
|
2019
|
|
|
2018
|
|
|
2019
|
|
|
2018
|
|
||||||||
Revenue:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
||||
Product
|
|
$
|
286
|
|
|
|
$
|
7,214
|
|
|
|
$
|
7,104
|
|
|
$
|
|
23,268
|
|
|
Service
|
|
|
402
|
|
|
|
|
310
|
|
|
|
|
1,427
|
|
|
|
|
834
|
|
|
Total revenue
|
|
|
688
|
|
|
|
|
7,524
|
|
|
|
|
8,531
|
|
|
|
|
24,102
|
|
|
Cost of revenue:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
||||
Product
|
|
|
9,812
|
|
|
|
|
5,005
|
|
|
|
|
16,439
|
|
|
|
|
14,162
|
|
|
Service
|
|
|
1,071
|
|
|
|
|
630
|
|
|
|
|
4,292
|
|
|
|
|
2,009
|
|
|
Total cost of revenue
|
|
|
10,883
|
|
|
|
|
5,635
|
|
|
|
|
20,731
|
|
|
|
|
16,171
|
|
|
Gross (loss) profit
|
|
|
(10,195
|
|
)
|
|
|
1,889
|
|
|
|
|
(12,200
|
|
)
|
|
|
7,931
|
|
|
Operating Expenses (Income)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
||||
Research and development
|
|
|
4,634
|
|
|
|
|
6,439
|
|
|
|
|
22,468
|
|
|
|
|
21,823
|
|
|
Sales and marketing
|
|
|
5,584
|
|
|
|
|
7,901
|
|
|
|
|
28,014
|
|
|
|
|
25,736
|
|
|
General and administrative
|
|
|
3,799
|
|
|
|
|
3,865
|
|
|
|
|
18,758
|
|
|
|
|
13,854
|
|
|
Amortization of intangible assets
|
|
|
2,547
|
|
|
|
|
2,624
|
|
|
|
|
10,301
|
|
|
|
|
10,868
|
|
|
Change in fair value of contingent consideration
|
|
|
136
|
|
|
|
|
(1,092
|
|
)
|
|
|
(9,553
|
|
)
|
|
|
(1,011
|
|
)
|
Restructuring and other charges
|
|
|
1,374
|
|
|
|
|
—
|
|
|
|
|
1,374
|
|
|
|
|
—
|
|
|
Goodwill impairment
|
|
|
—
|
|
|
|
|
—
|
|
|
|
|
78,969
|
|
|
|
|
—
|
|
|
In-process research and development impairment
|
|
|
—
|
|
|
|
|
—
|
|
|
|
|
7,912
|
|
|
|
|
—
|
|
|
Acquisition related costs
|
|
|
—
|
|
|
|
|
302
|
|
|
|
|
—
|
|
|
|
|
647
|
|
|
Loss (gain) from sale of SurgiBot assets, net
|
|
|
—
|
|
|
|
|
75
|
|
|
|
|
97
|
|
|
|
|
(11,840
|
|
)
|
Gain from sale of Autolap assets, net
|
|
|
(15,965
|
|
)
|
|
|
—
|
|
|
|
|
(15,965
|
|
)
|
|
|
—
|
|
|
Reversal of transfer fee accrual
|
|
|
—
|
|
|
|
|
—
|
|
|
|
|
—
|
|
|
|
|
(2,994
|
|
)
|
Total Operating Expenses
|
|
|
2,109
|
|
|
|
|
20,114
|
|
|
|
|
142,375
|
|
|
|
|
57,083
|
|
|
Operating Loss
|
|
|
(12,304
|
|
)
|
|
|
(18,225
|
|
)
|
|
|
(154,575
|
|
)
|
|
|
(49,152
|
|
)
|
Other Income (Expense)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
||||
Change in fair value of warrant liabilities
|
|
|
(788
|
|
)
|
|
|
10,118
|
|
|
|
|
2,248
|
|
|
|
|
(14,320
|
|
)
|
Interest income
|
|
|
23
|
|
|
|
|
418
|
|
|
|
|
582
|
|
|
|
|
1,400
|
|
|
Interest expense
|
|
|
(1,206
|
|
)
|
|
|
(810
|
|
)
|
|
|
(4,613
|
|
)
|
|
|
(4,208
|
|
)
|
Other (expense) income
|
|
|
(32
|
|
)
|
|
|
1,235
|
|
|
|
|
(967
|
|
)
|
|
|
1,126
|
|
|
Total Other Expense, net
|
|
|
(2,003
|
|
)
|
|
|
10,961
|
|
|
|
|
(2,750
|
|
)
|
|
|
(16,002
|
|
)
|
Loss before income taxes
|
|
$
|
(14,307
|
|
)
|
|
$
|
(7,264
|
|
)
|
|
$
|
(157,325
|
|
)
|
|
$
|
(65,154
|
|
)
|
Income tax benefit
|
|
|
575
|
|
|
|
|
823
|
|
|
|
|
3,124
|
|
|
|
|
3,377
|
|
|
Net loss
|
|
$
|
(13,732
|
|
)
|
|
$
|
(6,441
|
|
)
|
|
$
|
(154,201
|
|
)
|
|
$
|
(61,777
|
|
)
|
Other comprehensive loss
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
||||
Foreign currency translation gain (loss)
|
|
|
1,671
|
|
|
|
|
(1,039
|
|
)
|
|
|
(2,708
|
|
)
|
|
|
(3,690
|
|
)
|
Comprehensive loss
|
|
$
|
(12,061
|
|
)
|
|
$
|
(7,480
|
|
)
|
|
$
|
(156,909
|
|
)
|
|
$
|
(65,467
|
|
)
|
Net loss per share - basic and diluted
|
|
$
|
(0.69
|
|
)
|
|
$
|
(0.39
|
|
)
|
|
$
|
(8.69
|
|
)
|
|
$
|
(3.88
|
|
)
|
Weighted average common shares outstanding - basic and diluted
|
|
|
19,885
|
|
|
|
|
16,550
|
|
|
|
|
17,737
|
|
|
|
|
15,938
|
|
|
|
|
December 31,
|
|
|
December 31,
|
|
||||
|
|
2019
|
|
|
2018
|
|
||||
|
|
(Unaudited)
|
|
|
|
|
|
|||
Assets
|
|
|
|
|
|
|
|
|
||
Current Assets
|
|
|
|
|
|
|
|
|
||
Cash and cash equivalents
|
|
$
|
9,598
|
|
|
|
$
|
21,061
|
|
|
Short-term investments
|
|
|
—
|
|
|
|
|
51,790
|
|
|
Accounts receivable, net
|
|
|
620
|
|
|
|
|
8,560
|
|
|
Inventories
|
|
|
10,653
|
|
|
|
|
10,941
|
|
|
Interest receivable
|
|
|
—
|
|
|
|
|
26
|
|
|
Other current assets
|
|
|
7,084
|
|
|
|
|
9,205
|
|
|
Total Current Assets
|
|
|
27,955
|
|
|
|
|
101,583
|
|
|
Restricted cash
|
|
|
969
|
|
|
|
|
590
|
|
|
Inventories, net of current portion
|
|
|
7,594
|
|
|
|
|
—
|
|
|
Property and equipment, net
|
|
|
4,706
|
|
|
|
|
6,337
|
|
|
Intellectual property, net
|
|
|
28,596
|
|
|
|
|
39,716
|
|
|
In-process research and development
|
|
|
2,470
|
|
|
|
|
10,747
|
|
|
Goodwill
|
|
|
—
|
|
|
|
|
80,131
|
|
|
Other long term assets
|
|
|
2,489
|
|
|
|
|
203
|
|
|
Total Assets
|
|
$
|
74,779
|
|
|
|
$
|
239,307
|
|
|
Liabilities and Stockholders’ Equity
|
|
|
|
|
|
|
|
|
||
Current Liabilities
|
|
|
|
|
|
|
|
|
||
Accounts payable
|
|
$
|
3,579
|
|
|
|
$
|
4,433
|
|
|
Accrued expenses
|
|
|
8,553
|
|
|
|
|
9,619
|
|
|
Deferred revenue – current portion
|
|
|
818
|
|
|
|
|
1,733
|
|
|
Contingent consideration – current portion
|
|
|
73
|
|
|
|
|
72
|
|
|
Deferred consideration – MST Acquisition
|
|
|
—
|
|
|
|
|
5,962
|
|
|
Total Current Liabilities
|
|
|
13,023
|
|
|
|
|
21,819
|
|
|
Long Term Liabilities
|
|
|
|
|
|
|
|
|
||
Deferred revenue – less current portion
|
|
|
27
|
|
|
|
|
109
|
|
|
Contingent consideration – less current portion
|
|
|
1,011
|
|
|
|
|
10,565
|
|
|
Notes payable, net of debt discount
|
|
|
—
|
|
|
|
|
28,937
|
|
|
Warrant liabilities
|
|
|
2,388
|
|
|
|
|
4,636
|
|
|
Net deferred tax liabilities
|
|
|
1,392
|
|
|
|
|
4,720
|
|
|
Other long term liabilities
|
|
|
1,403
|
|
|
|
|
—
|
|
|
Total Liabilities
|
|
|
19,244
|
|
|
|
|
70,786
|
|
|
Commitments and Contingencies
|
|
|
|
|
|
|
|
|
||
Stockholders’ Equity
|
|
|
|
|
|
|
|
|
||
Common stock $0.001 par value, 750,000,000 shares authorized at
December 31, 2019 and December 31, 2018; 20,691,301 and
16,641,999 shares issued and outstanding at December 31, 2019 and
December 31, 2018, respectively
|
|
|
21
|
|
|
|
|
17
|
|
|
Additional paid-in capital
|
|
|
720,484
|
|
|
|
|
676,572
|
|
|
Accumulated deficit
|
|
|
(663,600
|
|
)
|
|
|
(509,406
|
|
)
|
Accumulated other comprehensive (loss) income
|
|
|
(1,370
|
|
)
|
|
|
1,338
|
|
|
Total Stockholders’ Equity
|
|
|
55,535
|
|
|
|
|
168,521
|
|
|
Total Liabilities and Stockholders’ Equity
|
|
$
|
74,779
|
|
|
|
$
|
239,307
|
|
|
|
|
Twelve Months Ended
|
|
|||||||
|
|
December 31,
|
|
|||||||
|
|
2019
|
|
|
2018
|
|
||||
Operating Activities
|
|
|
(Unaudited)
|
|
|
|
|
|
||
Net loss
|
|
$
|
(154,201
|
|
)
|
|
$
|
(61,777
|
|
)
|
Adjustments to reconcile net loss to net cash and cash equivalents used in
operating activities:
|
|
|
|
|
|
|
|
|
||
Gain from sale of AutoLap assets, net
|
|
|
(15,965
|
|
)
|
|
|
—
|
|
|
Loss (gain) from sale of SurgiBot assets, net
|
|
|
97
|
|
|
|
|
(11,840
|
|
)
|
Goodwill and intangible assets impairment
|
|
|
86,881
|
|
|
|
|
—
|
|
|
Depreciation
|
|
|
2,166
|
|
|
|
|
2,420
|
|
|
Amortization of intangible assets
|
|
|
10,301
|
|
|
|
|
10,868
|
|
|
Amortization of debt discount and debt issuance costs
|
|
|
1,513
|
|
|
|
|
725
|
|
|
Amortization of short-term investment discount
|
|
|
(327
|
|
)
|
|
|
(351)
|
|
|
Stock-based compensation
|
|
|
11,508
|
|
|
|
|
9,039
|
|
|
Inventory write-down related to restructuring
|
|
|
7,408
|
|
|
|
|
—
|
|
|
Inventory write-down
|
|
|
1,523
|
|
|
|
|
|
|
|
Bad debt expense
|
|
|
1,634
|
|
|
|
|
—
|
|
|
Interest expense on deferred consideration – MST acquisition
|
|
|
756
|
|
|
|
|
—
|
|
|
Deferred tax benefit
|
|
|
(3,224
|
|
)
|
|
|
(3,377
|
|
)
|
Loss on extinguishment of debt
|
|
|
1,006
|
|
|
|
|
1,400
|
|
|
Change in fair value of warrant liabilities
|
|
|
(2,248
|
|
)
|
|
|
14,320
|
|
|
Change in fair value of contingent consideration
|
|
|
(9,553
|
|
)
|
|
|
(1,011
|
|
)
|
Reversal of transfer fee accrual
|
|
|
—
|
|
|
|
|
(2,994
|
|
)
|
Changes in operating assets and liabilities, net of effect of acquisition:
|
|
|
|
|
|
|
|
|
||
Accounts receivable
|
|
|
6,083
|
|
|
|
|
(7,225
|
|
)
|
Interest receivable
|
|
|
26
|
|
|
|
|
54
|
|
|
Inventories
|
|
|
(16,404
|
|
)
|
|
|
(2,145
|
|
)
|
Other current and long term assets
|
|
|
(655
|
|
)
|
|
|
(325
|
|
)
|
Accounts payable
|
|
|
(668
|
|
)
|
|
|
767
|
|
|
Accrued expenses
|
|
|
(1,180
|
|
)
|
|
|
2,134
|
|
|
Deferred revenue
|
|
|
(959
|
|
)
|
|
|
825
|
|
|
Other long term liabilities
|
|
|
998
|
|
|
|
|
—
|
|
|
Net cash and cash equivalents used in operating activities
|
|
|
(73,484
|
|
)
|
|
|
(48,493
|
|
)
|
Investing Activities
|
|
|
|
|
|
|
|
|
||
Proceeds from sale of AutoLap assets
|
|
|
15,965
|
|
|
|
|
—
|
|
|
Purchase of short-term investments
|
|
|
(12,883
|
|
)
|
|
|
(55,439
|
|
)
|
Proceeds from maturities of short-term investments
|
|
|
65,000
|
|
|
|
|
4,000
|
|
|
Payment for acquisition of a business
|
|
|
—
|
|
|
|
|
(5,800
|
|
)
|
Proceeds related to sale of SurgiBot assets, net
|
|
|
—
|
|
|
|
|
4,496
|
|
|
Purchase of property and equipment
|
|
|
(437
|
|
)
|
|
|
(770
|
|
)
|
Proceeds from sale of property and equipment
|
|
|
—
|
|
|
|
|
32
|
|
|
Net cash and cash equivalents provided by (used in) investing activities
|
|
|
67,645
|
|
|
|
|
(53,481
|
|
)
|
Financing Activities
|
|
|
|
|
|
|
|
|
||
Payment of notes payable
|
|
|
(31,425
|
|
)
|
|
|
(15,305
|
|
)
|
Proceeds from issuance of debt and warrants, net of issuance costs
|
|
|
—
|
|
|
|
|
28,507
|
|
|
Payment of contingent consideration
|
|
|
—
|
|
|
|
|
(770
|
|
)
|
Proceeds from issuance of common stock and warrants, net of issuance costs
|
|
|
25,777
|
|
|
|
|
279
|
|
|
Taxes paid related to net share settlement of vesting of restricted stock units
|
|
|
(499
|
|
)
|
|
|
(1,662
|
|
)
|
Proceeds from issuance of common stock related to sale of SurgiBot assets
|
|
|
—
|
|
|
|
|
3,000
|
|
|
Proceeds from exercise of stock options and warrants
|
|
|
538
|
|
|
|
|
12,403
|
|
|
Net cash and cash equivalents (used in) provided by financing activities
|
|
|
(5,609
|
|
)
|
|
|
26,452
|
|
|
Effect of exchange rate changes on cash and cash equivalents
|
|
|
364
|
|
|
|
|
(433
|
|
)
|
Net (decrease) increase in cash, cash equivalents and restricted cash
|
|
|
(11,084
|
|
)
|
|
|
(75,955
|
|
)
|
Cash, cash equivalents and restricted cash, beginning of period
|
|
|
21,651
|
|
|
|
|
97,606
|
|
|
Cash, cash equivalents and restricted cash, end of period
|
|
$
|
10,567
|
|
|
|
$
|
21,651
|
|
|
Supplemental Disclosure for Cash Flow Information
|
|
|
|
|
|
|
|
|
||
Interest paid
|
|
$
|
2,187
|
|
|
|
$
|
1,730
|
|
|
Supplemental Schedule of Non-cash Investing and Financing Activities
|
|
|
|
|
|
|
|
|
||
Transfer of inventories to property and equipment
|
|
$
|
486
|
|
|
|
$
|
2,160
|
|
|
Transfer of property and equipment to inventories
|
|
$
|
323
|
|
|
|
$
|
637
|
|
|
Reclass of warrant liability to common stock and additional paid-in capital
|
|
$
|
—
|
|
|
|
$
|
23,774
|
|
|
Cashless exercise of warrants
|
|
$
|
—
|
|
|
|
$
|
4,272
|
|
|
Issuance of common stock related to MST acquisition
|
|
$
|
6,600
|
|
|
|
$
|
8,300
|
|
|
Proceeds from sale of AutoLap assets exchanged for settlement of Company obligations
|
|
$
|
1,000
|
|
|
|
$
|
—
|
|
|
Deferred consideration – MST acquisition
|
|
$
|
—
|
|
|
|
$
|
5,962
|
|
|
Reconciliation of Non-GAAP Measures
|
||||||||||||||||
Adjusted Net Loss and Net Loss per Share
|
||||||||||||||||
(in thousands except per share amounts)
|
||||||||||||||||
(Unaudited)
|
||||||||||||||||
|
|
|
|
|
|
|
|
|
|
|
|
|
||||
|
|
|
Three Months Ended
|
|
|
Twelve Months Ended
|
||||||||||
|
|
|
December 31,
|
|
|
December 31,
|
||||||||||
|
|
2019
|
|
2018
|
|
2019
|
|
2018
|
||||||||
(Unaudited, U.S. Dollars, in thousands)
|
|
|
|
|
|
|
|
|
|
|
|
|||||
Net loss (GAAP)
|
$
|
(13,732)
|
|
|
$
|
(6,441)
|
|
|
$
|
(154,201)
|
|
|
$
|
(61,777)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
||||
Adjustments
|
|
|
|
|
|
|
|
|
|
|
|
|||||
|
Gain from sale of AutoLap assets, net
|
|
(15,965)
|
|
|
|
—
|
|
|
|
(15,965)
|
|
|
|
—
|
|
|
Loss (gain) from sale of SurgiBot assets, net
|
|
—
|
|
|
75
|
|
|
97
|
|
|
|
(11,840)
|
|
||
|
Amortization of intangible assets
|
|
2,547
|
|
|
|
2,624
|
|
|
|
10,301
|
|
|
|
10,868
|
|
|
Change in fair value of contingent consideration
|
|
136
|
|
|
|
(1,092)
|
|
|
|
(9,553)
|
|
|
|
(1,011)
|
|
|
Acquisition related costs
|
|
—
|
|
|
|
302
|
|
|
|
—
|
|
|
|
647
|
|
|
Goodwill impairment
|
|
—
|
|
|
|
—
|
|
|
|
78,969
|
|
|
|
—
|
|
|
In-process research and development impairment
|
|
—
|
|
|
|
—
|
|
|
|
7,912
|
|
|
|
—
|
|
|
Reversal of transfer fee accrual
|
|
—
|
|
|
|
—
|
|
|
|
—
|
|
|
|
(2,994)
|
|
|
Change in fair value of warrant liabilities
|
|
788
|
|
|
|
(10,118)
|
|
|
|
(2,248)
|
|
|
|
14,320
|
|
|
Restructuring and other charges
|
|
1,374
|
|
|
|
—
|
|
|
|
1,374
|
|
|
|
—
|
|
|
Inventory write-down related to restructuring
|
|
7,408
|
|
|
|
—
|
|
|
|
7,408
|
|
|
|
—
|
|
|
Loss on extinguishment of debt
|
|
1,006
|
|
|
|
—
|
|
|
|
1,006
|
|
|
|
1,400
|
|
Adjusted net loss (Non-GAAP)
|
$
|
(16,438)
|
|
|
$
|
(14,650)
|
|
|
$
|
(74,900)
|
|
|
$
|
(50,387)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
||||
|
|
|
Three Months Ended
|
|
|
Twelve Months Ended
|
||||||||||
|
|
|
December 31,
|
|
|
December 31,
|
||||||||||
(Unaudited, per basic share)
|
2019
|
|
2018
|
|
2019
|
|
2018
|
|||||||||
Net loss per share (GAAP)
|
$
|
(0.690)
|
|
|
$
|
(0.390)
|
|
|
$
|
(8.690)
|
|
|
$
|
(3.880)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
||||
Adjustments
|
|
|
|
|
|
|
|
|
|
|
|
|||||
|
Gain from sale of AutoLap assets, net
|
|
(0.800)
|
|
|
|
—
|
|
|
|
(0.900)
|
|
|
|
—
|
|
|
Loss (gain) from sale of SurgiBot assets, net
|
|
—
|
|
|
|
0.00
|
|
|
|
0.01
|
|
|
|
(0.740)
|
|
|
Amortization of intangible assets
|
|
0.13
|
|
|
|
0.16
|
|
|
|
0.58
|
|
|
|
0.68
|
|
|
Change in fair value of contingent consideration
|
|
0.01
|
|
|
|
(0.070)
|
|
|
|
(0.540)
|
|
|
|
(0.060)
|
|
|
Acquisition related costs
|
|
—
|
|
|
|
0.02
|
|
|
|
—
|
|
|
|
0.04
|
|
|
Goodwill impairment
|
|
—
|
|
|
|
—
|
|
|
|
4.45
|
|
|
|
—
|
|
|
In-process research and development impairment
|
|
—
|
|
|
|
—
|
|
|
|
0.45
|
|
|
|
—
|
|
|
Reversal of transfer fee accrual
|
|
—
|
|
|
|
—
|
|
|
|
—
|
|
|
|
(0.190)
|
|
|
Change in fair value of warrant liabilities
|
|
0.04
|
|
|
|
(0.610)
|
|
|
|
(0.130)
|
|
|
|
0.90
|
|
|
Restructuring and other charges
|
|
0.07
|
|
|
|
—
|
|
|
|
0.08
|
|
|
|
—
|
|
|
Inventory write-down related to restructuring
|
|
0.37
|
|
|
|
—
|
|
|
|
0.42
|
|
|
|
—
|
|
|
Loss on extinguishment of debt
|
|
0.05
|
|
|
|
—
|
|
|
|
0.06
|
|
|
|
0.09
|
|
Adjusted net loss per share (Non-GAAP)
|
$
|
(0.830)
|
|
|
$
|
(0.890)
|
|
|
$
|
(4.220)
|
|
|
$
|
(3.160)
|
|